Industry Partner Program now available!
The APLAR 2025 official program is scheduled in the Japanese time zone (UTC+9). To check the program times in your location, use a time zone converter.
As more information becomes available – this page will be updated so please make sure to check back regularly.
Program is best viewed on a desktop or large landscape screen.
| Plenary / Concurrent 1 | Concurrent 2 | Concurrent 3 | Concurrent 4 | Concurrent 5 | Concurrent 6 | |
|---|---|---|---|---|---|---|
|
0830-0915 |
|
Breakfast symposium 1
Rheumatoid arthritis in the elderly: Characteristics and treatment considerations |
Breakfast symposium 2 Biosimilars in rheumatoid arthritis |
Breakfast symposium 3 Future Directions in MAS and Still’s Disease: Challenges and Opportunities |
|
|
|
|
|
|
||||
|
0920-1050 |
Plenary session 1
View main program |
|||||
|
1050-1110 |
Break and poster viewing |
|||||
|
1110-1215 |
Morning symposium 1
Title coming soon |
Morning symposium 2
From SLE to LN – preventing organ damage and progression : an Asian perspective |
Morning symposium 3
Title coming soon |
|
Morning symposium 5
Title coming soon |
Morning symposium 6
Title coming soon |
|
|
|
|
|
|
||
|
1220-1335 |
||||||
|
1340-1510 |
|
|
Lunch symposium 2
Etanercept biosimilar product |
|
|
|
|
|
||||||
|
1515-1630 |
||||||
|
1630-1655 |
Break and poster viewing |
|||||
|
1655-1810 |
||||||
|
1815-1915 |
|
|
Evening symposium 3
Pathophysiology and treatment strategies in systemic lupus erythematosus / Lupus Nephritis |
Evening symposium 4
Title coming soon |
|
Evening symposium 6
Treatment Strategy for Osteoporosis with Rheumatoid Arthritis |
|
|
|
|
||||
|
1930-late |
AYR Networking Reception (members and invitation only) |
|||||
| Plenary / Concurrent 1 | Concurrent 2 | Concurrent 3 | Concurrent 4 | Concurrent 5 | Concurrent 6 | |
|---|---|---|---|---|---|---|
|
0830-0915 |
|
Breakfast symposium 6 Improving conventional therapy for patients with rheumatoid arthritis by subcutaneous MTX |
Breakfast symposium 7 The importance of IL-6 focusing on Rheumatoid Arthritis and Various Autoimmune-related diseases |
Breakfast symposium 8 Title coming soon |
Breakfast symposium 9 Title coming soon |
|
|
|
|
|
|
|||
|
0920-1050 |
Plenary session 2 View main program |
|||||
|
1050-1110 |
Break and poster viewing |
|||||
|
1110-1215 |
Morning symposium 7 Title coming soon |
|
Morning symposium 9 Update on SSc-ILD |
Morning symposium 10 The role of CANAKINUMAB in the Still’s disease treatment paradigm |
Morning symposium 11 The mission for remission: what is now possible for our patients? |
Morning symposium 12 The role and clinical significance of IL-17A and IL-17F in the pathogenesis of SpA |
|
|
|
|
|
|
||
|
1220-1335 |
||||||
|
1340-1510 |
|
|
Lunch symposium 7 The current screening, monitoring, and treatment for RA-ILD |
Lunch symposium 8 Go Beyond T2T with harmony |
|
|
|
|
|
|||||
|
1515-1630 |
||||||
|
1630-1655 |
Break and poster viewing |
|||||
|
1655-1810 |
||||||
|
1900-late |
Joint Presidential Gala dinner |
|||||
